The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.

MaaT Pharma is focused on developing microbiome-related therapies and its lead candidate is MaaT013, a treatment for acute ...

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...

The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, ...

Following a positive meeting with the FDA, BrainChild is getting ready to initiate a pivotal registration trial with its lead ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US. Ryoncil (remestemcel-L-rknd) has been granted approval by the FDA for ...